NCT07230067 is a clinical trial of SAT patients in Sepsis, sponsored by Nanfang Hospital, Southern Medical University.

Who is sponsoring NCT07230067?

NCT07230067 is sponsored by Nanfang Hospital, Southern Medical University.

What drugs are being tested in NCT07230067?

Interventions in NCT07230067: SAT patients.

What condition does NCT07230067 study?

NCT07230067 studies Sepsis, Sepsis and Coagulopathy.

Is NCT07230067 still recruiting?

NCT07230067 is currently recruiting now. Last updated 30 January 2026.

Last reviewed 2026-01-30 · How we verify

NCT07230067

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sepsis-associated Thrombocytopenia and Platelet Transfusion （STAPT）

Recruiting now Last updated 30 January 2026

What this trial tests

trial testing SAT patients in Sepsis in 1,500 participants. Currently enrolling.

Timeline

15 November 2025

Primary endpoint
30 December 2026

31 March 2027

Quick facts

Lead sponsor	Nanfang Hospital, Southern Medical University
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	1,500
Start date	15 November 2025
Primary completion	30 December 2026
Estimated completion	31 March 2027
Sites	1 location across China

Drugs / interventions tested

SAT patients

Conditions studied

Sepsis — all drugs for Sepsis →
Sepsis and Coagulopathy — all drugs for Sepsis and Coagulopathy →

Sponsor

Nanfang Hospital, Southern Medical University

Who can join

18 and older, any sex, with Sepsis or Sepsis and Coagulopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Currently, there are no multicenter studies on platelet transfusion for SAT patients, and the benefits and risks of platelet transfusion still require further validation based on large-sample data. In summary, investigating the correlation between platelet transfusion during ICU stay and 28-day mortality in SAT patients, as well as evaluating the impact of platelet transfusion on bleeding, thrombotic events, and inflammation control, is of great significance for optimizing SAT management strategies. This study aims to analyze the effect of platelet transfusion on the prognosis of SAT patients, thereby providing an evidence-based foundation for clinical decision-making.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Sepsis

Currently open trials in the same condition.

NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting

Other Nanfang Hospital, Southern Medical University trials

Trials by the same sponsor.

NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07230067 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
Last refreshed: 30 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07230067.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing